Research company Chosa Oncology has initiated a research collaboration with Icahn School of Medicine at Mount Sinai in New York to investigate which lung cancer patients benefit from platinum-based treatment in combination with immunotherapy, according to a press release.The collaboration will evaluate the company’s biomarker Platin-DRP in patients with advanced non-small cell lung cancer. "We will investigate whether Platin-DRP is associated with survival, with the aim of enabling more individualized treatment strategies," comments Fred Hirsch, professor and CEO of the Center for Thoracic Oncology at Mount Sinai Tisch Cancer Center in New York."We are moving from trial and error toward prediction. This study evaluates Platin-DRP in the most important current treatment setting in lung cancer and may help identify which patients truly benefit from chemo-immunotherapy," says Peter Buhl Jensen, CEO of Chosa Oncology.